scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences
Rhea-AI Summary
scPharmaceuticals (Nasdaq: SCPH), a pharmaceutical company focused on cardiorenal healthcare innovation, has announced its participation in two major investor conferences in March 2025. John Tucker, President and CEO, will represent the company at both events.
The scheduled appearances include:
- A fireside chat at the 45th Annual TD Cowen Healthcare Conference on March 5 at 11:10AM ET
- A corporate presentation at the Leerink Partners 2025 Global Healthcare Conference on March 11 at 2:20PM ET
Both presentations will be accessible via webcast through the company's website under the Investor Relations section.
Positive
- None.
Negative
- None.
News Market Reaction – SCPH
On the day this news was published, SCPH declined 1.52%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will present at the following upcoming investor conferences:
- 45th Annual TD Cowen Healthcare Conference: Fireside chat on Wednesday, March 5 at 11:10AM ET.
- Leerink Partners 2025 Global Healthcare Conference: Corporate presentation on Tuesday, March 11 at 2:20PM ET.
A webcast of the presentations can be accessed here or under “News & Events” in the Investor Relations section of the Company’s website, www.scPharmaceuticals.com.
About scPharmaceuticals
At scPharmaceuticals, we are powered by passion, driven by patient care. Our Mission is focused on advancing cardiorenal care through innovative, integrated treatments that address unmet patient needs.
Our goal is to become the foremost advocate for patient-centric cardiorenal care, driving global health improvements through specialized, multidisciplinary approaches. scPharmaceuticals is expanding its reach, offering integrated therapies and products that address diverse healthcare needs and potentially improve the lives of our patients. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.
Katherine Miranda
scPharmaceuticals Inc., 781-301-6869
kmiranda@scpharma.com
Investors:
Nick Colangelo
Gilmartin Group, 339-225-1047
Nick@GilmartinIR.com
